TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03517839

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Inspiratory muscle trainig
Description: Inspiratory muscle training in the training group will be administered at least 5 days a week, 15 minutes twice a day, beginning at 30% of the MIP for 8 weeks. Patients will come to the control once a week, the MIP values will be re-measured and the new training intensity will be determined at 30% of the new value. For the control group, a fixed training session will be given for at least 5 days a week, 15 minutes twice a day, not exceeding 15% of the MIP for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle trainig
Description: Inspiratory muscle training in the training group will be administered at least 5 days a week, 15 minutes twice a day, beginning at 30% of the MIP for 8 weeks. Patients will come to the control once a week, the MIP values will be re-measured and the new training intensity will be determined at 30% of the new value. For the control group, a fixed training session will be given for at least 5 days a week, 15 minutes twice a day, not exceeding 15% of the MIP for 8 weeks.
Study: NCT00426816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-649868
Description: Active compound at doses of 10mg, 30mg and 60mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match SB-649868
Study: NCT00776594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy
Description: leuprolide: 22.5mg given IM every 3 months for a total of 6 months or, goserelin acetate: 10.8mg given SC every 3 months for a total of 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy
Description: leuprolide: 22.5mg given IM every 3 months for a total of 6 months or, goserelin acetate: 10.8mg given SC every 3 months for a total of 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide
Description: 50mg orally daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide
Description: 50mg orally daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 15mg/ks given IV every three weeks for a total of 8 infusions over 6 months
Study: NCT01196468

Intervention type: OTHER
Intervention: HIV test (serological or salivary)
Description: An HIV test will be offered to all patients accessing the healthcare setting for care of the indicator condition

Intervention type: OTHER
Intervention: HIV test (serological or salivary)
Description: An HIV test will be offered to all patients accessing the healthcare setting for care of the indicator condition

Intervention type: OTHER
Intervention: HIV test (serological or salivary)
Description: An HIV test will be offered to all patients accessing the healthcare setting for care of the indicator condition

Intervention type: OTHER
Intervention: HIV test (serological or salivary)
Description: An HIV test will be offered to all patients accessing the healthcare setting for care of the indicator condition

Intervention type: OTHER
Intervention: HIV test (serological or salivary)
Description: An HIV test will be offered to all patients accessing the healthcare setting for care of the indicator condition

Intervention type: OTHER
Intervention: Interview
Description: Demographic data will be collected for each patient consenting to an HIV test. With informed written consent, additional data will be collected from patients via focussed interview. Data comprises: previous medical history, previous health seeking behaviours, previous HIV testing history, previous viral hepatitis testing/diagnosis history, and assessment of HIV acquisition risk factors
Study: NCT02155868

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correction rSO2 desaturation.
Description: Predefined protocol of interventions for correcting rSO2 desaturation (\< 60%) during cardiac surgery and the first six hours after it.~In case of rSO2 decrease less than 60% correct:~head position; position of aortic,venous cannulae and central venous catheters; partial pressure of carbon dioxide in arterial blood \< 35 mmHg; mean arterial pressure \< 60 mmHg; central venous pressure \> 10 mmHg; cardiac index \< 2.0 l/min/m2; mixed venous oxygen saturation \< 60%; hemoglobin \< 65 g/L during cardiopulmonary bypass or hemoglobin \< 90 g/L after cardiopulmonary bypass; decrease cerebral O2 consumption.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard treatment
Description: Standard treatment
Study: NCT01196468

Intervention type: OTHER
Intervention: Interview
Description: Demographic data will be collected for each patient consenting to an HIV test. With informed written consent, additional data will be collected from patients via focussed interview. Data comprises: previous medical history, previous health seeking behaviours, previous HIV testing history, previous viral hepatitis testing/diagnosis history, and assessment of HIV acquisition risk factors

Intervention type: OTHER
Intervention: Interview
Description: Demographic data will be collected for each patient consenting to an HIV test. With informed written consent, additional data will be collected from patients via focussed interview. Data comprises: previous medical history, previous health seeking behaviours, previous HIV testing history, previous viral hepatitis testing/diagnosis history, and assessment of HIV acquisition risk factors

Intervention type: OTHER
Intervention: Interview
Description: Demographic data will be collected for each patient consenting to an HIV test. With informed written consent, additional data will be collected from patients via focussed interview. Data comprises: previous medical history, previous health seeking behaviours, previous HIV testing history, previous viral hepatitis testing/diagnosis history, and assessment of HIV acquisition risk factors

Intervention type: OTHER
Intervention: Interview
Description: Demographic data will be collected for each patient consenting to an HIV test. With informed written consent, additional data will be collected from patients via focussed interview. Data comprises: previous medical history, previous health seeking behaviours, previous HIV testing history, previous viral hepatitis testing/diagnosis history, and assessment of HIV acquisition risk factors
Study: NCT00053976

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daclizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Study: NCT01850524

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone tablets.
Study: NCT00053976

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methylprednisolone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04308239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reactive balance training
Description: Participants were exposed to simulated trips and slips under safe, controlled conditions in order to practice their reactive response to these common balance perturbations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Otago Balance Training
Description: Balance exercises and strength exercises using ankle weights, and were progressively increased as performance improved by increasing ankle weights or the difficulty of the balance exercises (e.g., not holding onto a wall or support).
Study: NCT03252444

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conscious control
Description: Conscious control of the scapula is important and can correct neuromuscular coordination as well as strength deficits. The strategy in learning control of scapula into normal orientation can be facilitated by manual guides and/or external cues

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conscious control+biofeedback
Description: In electromyography (EMG) biofeedback training, electronic equipment is used to reveal instantaneously certain physiological events.
Study: NCT00113672

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase healthy activity and increase healthy eating
Description: Increase participants to 60 minutes of activity per day and 5 fruits and vegetables per day over a 3 week prescription phase

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decrease unhealthy activity and increase healthy eating
Description: Decrease sedentary activity by 90 minutes per day and increase fruits and vegetables to 5 servings per day over the course of a 3 week prescription phase

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase physical activity and decrease unhealthy eating
Description: Increase physical activity up to 60 minutes per day and decrease saturated fat to an average of 8% per day over the course of a 3 week prescription phase

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decrease sedentary activity and decrease unhealthy eating
Description: Decrease sedentary activity by 90 minutes per day and decrease saturated fat to and average of 8% per day over the course of a 3 week prescription phase
Study: NCT02744495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone
Description: Prophylaxis if risk score is over 2. Prophylaxis of postoperative nausea and vomiting by betamethasone / Celestene (4mg) and/or droperidol / Droleptan (0.625mg) immediately after cardiac surgery, depending on risk factors in the intervention arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droperidol
Description: Prophylaxis if risk score is over 2. Prophylaxis of postoperative nausea and vomiting by betamethasone / Celestene (4mg) and/or droperidol / Droleptan (0.625mg) immediately after cardiac surgery, depending on risk factors in the intervention arm.
Study: NCT04034719

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: portage scarf
Description: Parents will be carried their newborn with the portage scarf provided by the department.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual practice
Description: Parents will be carried their newborn as their usual practice.
Study: NCT00327015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Coated Tablets, Oral, 10 mg, Daily (6 months ST, 12 months LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Coated Tablets, Oral, 10 mg, Daily (6 months ST, 12 months LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Coated tablets, PO, 5 mg, Daily (6 months ST, 12 months LT)
Study: NCT03465579

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: pelvic MRI
Description: multi-parametric pelvic MRI
Study: NCT00327015

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Coated tablets, Oral, 500 mg, Daily (6 months ST, 12 months LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Coated tablets, Oral, 500 mg, Daily (6 months ST, 12 months LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Coated tablets, Oral, 500 mg, Daily (6 months ST, 12 months LT)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Coated tablets, Oral, 0 mg, Daily (6 months ST, 12 months LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Coated tablets, Oral, 0 mg, Daily (6 months ST, 12 months LT)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: Tablets, Oral, 15-45 mg, as needed (12 months LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: Tablets, Oral, 15-45 mg, as needed (12 months LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: Tablets, Oral, 15-45 mg, as needed (12 months LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: Tablets, Oral, 15-45 mg, as needed (12 months LT)
Study: NCT03465579

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: pelvic MRI
Description: multi-parametric pelvic MRI

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 68Ga-PSMA PET/CT
Description: 68Ga-PSMA PET/CT

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 68Ga-PSMA PET/CT
Description: 68Ga-PSMA PET/CT

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 68Ga-PSMA PET/CT
Description: 68Ga-PSMA PET/CT
Study: NCT01850524

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide capsules.
Study: NCT03785002

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Description: 24 strength training sessions, with approximately 1 hour duration, that will occur 2x/week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Description: 24 strength training sessions, with approximately 1 hour duration, that will occur 2x/week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protein intake
Description: Guidance on the adequacy of protein intake (at least 20g of protein in breakfast, lunch and dinner)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein intake
Description: Guidance on the adequacy of protein intake (at least 20g of protein in breakfast, lunch and dinner)
Study: NCT03465579

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 68Ga-PSMA PET/CT
Description: 68Ga-PSMA PET/CT
Study: NCT03222102

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phasix mesh
Description: After the closure of the Abdomen, Phasix mesh will be placed and affixed on the exposed fascia.
Study: NCT03428477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icosapent Ethyl
Description: Composition: soft amber to light yellow, oblong gelatin capsules. One capsule contains 1g pure EPA-EE Dose: 4 capsules per day
Study: NCT00774644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500mg
Study: NCT03428477

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Composition: soft, amber to light yellow, oblong gelatin capsules containing light mineral oil:~Dose: 4 capsules per day
Study: NCT03904589

Intervention type: DIAGNOSTIC_TEST
Intervention: Quality of Life assessment
Description: Quality of life will be assessed by means of the Seattle Angina Questionnaire and the Patient Health Questionnaire.
Study: NCT02552303

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Cognitive Behavioral Therapy for Insomnia.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Cognitive Behavioral Therapy for Insomnia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Armodafinil
Description: Active medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Armodafinil
Description: Active medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Nuvigil (armodafinil)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Nuvigil (armodafinil)
Study: NCT01325454

Intervention type: DEVICE
Intervention: pleural pigtail drainage
Description: With the guidance of chest US, 50 ml of pleural fluid was collected using a standard thoracentesis technique immediately or within 24 hr after hospitalization. When pleural effusion was multi-loculated, the fluid was aspirated from the largest loculus. Routine analyses of pleural fluid for total leukocytes, cell differentials of leukocytes, pH value, and levels of protein, glucose and LDH were performed in addition to cytological and microbiologic examination of pleural fluid.The rest of pleural fluid samples were mixed with 3.8 % sodium citrate in a 9:1 ratio of pleural fluid to citrate. The sodium citrate-mixed pleural fluid specimens were immersed in ice immediately and then centrifuged at 2,500 g for 10 minutes. The cell-free supernatants of pleural fluid were frozen at -70℃ immediately after centrifuge for later measurements. The commercially available enzyme-linked immunosorbent assay kits were used to measure the effusion levels of VEGF, IL-8 , tPA and PAI-1.
Study: NCT04042051

Intervention type: DRUG
Group type: OTHER
Intervention: Copanlisib
Description: Copanlisib is supplied as lyophilized preparation in a 6mL injection vial. The total amount of copanlisib per vial is 60mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. Copanlisib will be administered on Days 1 (and 8 and 15 \[according to the dose escalation scheme\]) of each 21-day cycle. Copanlisib will be administered first over 60 minutes followed by the infusion of trastuzumab emtansine.

Intervention type: DRUG
Group type: OTHER
Intervention: Trastuzumab emtansine
Description: Trastuzumab emtansine 3.6mg/kg IV infusion on Day 1 of each 21-day treatment cycle.
Study: NCT01538979

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BM32
Description: Subcutaneous injection of 20 micrograms of each of the protein components of BM32 adsorbed on 0.6 mg of aluminum hydroxide every 4 weeks for a total of 3 injections before each pollen season and one boost injection after pollen season

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BM32
Description: Subcutaneous injection of 40 micrograms of each of the protein components of BM32 adsorbed on 1.2 mg of aluminum hydroxide every 4 weeks for a total of 3 injections before each pollen season and one boost injection after pollen season

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of 1.2 mg of aluminum hydroxide suspension every four weeks before each pollen season and one injection after pollen season for a total of 7 injections
Study: NCT04164017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-guided FNB with Syringe Suction
Description: For each case, FNB will be performed using two punctures: one with 20mL syringe suction and another without aspiration. The order in which they will be performed will be known only by the performing physician and the nursing team at the time that FNB is proposed. This information will be concealed from the pathologist responsible for sample analysis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guided FNB without Syringe Suction
Description: For each case, FNB will be performed using two punctures: one with 20mL syringe suction and another without aspiration. The order in which they will be performed will be known only by the performing physician and the nursing team at the time that FNB is proposed. This information will be concealed from the pathologist responsible for sample analysis.
Study: NCT00561158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eat Well Live Well Nutrition Program
Description: 12 sessions (6 group and 6 individual)over a period of 3 months with a 3 month follow-up period. The group sessions involve active learning exercises crucial to learning and utilizing nutrition information.~The group sessions included are:~* Rate Your Plate: determining high fat foods~* Label Reading: reading food labels~* Comparison Shopping: using unit pricing labels maximize nutritional value on a limited income~* Recipe Modification: preparing old recipes in new ways to reduce fat~* Eating Out: order healthier fast foods~* Coping with High Risk Situations: coping with situations in which these new habits may be threatened~Six individual sessions will introduce participants to low fat eating patterns or ways to lower fat in their diet, including:~* Substituting fat-modified foods for high fat foods~* Avoiding fat as a seasoning or flavoring~* Avoiding fried foods~* Modifying meat~* Replacing high fat foods with fruits, vegetables, grains and breads
Study: NCT03673085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN128
Description: CN128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN128
Description: CN128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN128
Description: CN128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN128
Description: CN128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN128
Description: CN128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN128
Description: CN128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN128
Description: CN128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN128
Description: CN128

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The tablets without CN128

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The tablets without CN128

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The tablets without CN128

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The tablets without CN128

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The tablets without CN128

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The tablets without CN128

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The tablets without CN128

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The tablets without CN128
Study: NCT05175222

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Laser therapy
Description: Patients receive laser therapy in 7 points in oral cavity every day from the first day of conditioning chemotherapy till the second day post HSCT. Each point is irradiated for 1 minute.
Study: NCT00740012

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Other capillary sample
Description: 5-7 minutes after the alarm clock or the nurse the doctoral candidate takes another capillary sample for a laboratory glucose determination (EBIOS, Eppendorf, Hamburg, Germany) analyzer.
Study: NCT03571412

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive Transcranial Magnetic Stimulation
Description: Subject will receive 5Hz LDLPFC or 5Hz DMPFC rTMS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive Transcranial Magnetic Stimulation
Description: Subject will receive 5Hz LDLPFC or 5Hz DMPFC rTMS
Study: NCT01146522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCQ908

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01808534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palifosfamide
Description: Given IV